To all the shareholders and partners of Zhongyuan Biotechnology holding Group:  On September 6th 2019, Zhongyuan Biotech has completed all IPO application documents and the procedures required by the SEC (US Securities and Exchange Commission).

On June 29, 2020 EDT, The Securities and Exchange Commission (" SEC ") approved and declared effective the Prospectus for the U.S. Initial public Offering of ZHONG YUAN BIO-TECHNOLOGY HOLDINGS LIMITED.

On March 8, 2021 EDT, Zhongyuan Biotech was officially approved by the U.S. Financial Regulatory Authority (FINRA) to go public, and the stock will trade under the ticker symbol: ZHYBF. This is a major milestone on the way to listing on NASDAQ, and it will be officially traded one week later.

In the morning of July 3rd, 2019, at the Occupational Safety and Health Research Center of the National Health Commission, Baofeng Biotech (Beijing) Co., Ltd.

As a leader in the nervonic acid industry, in recent years, Baofeng Biotech has not only brought brain health products to everyone, but has also cooperated with the Wei Ai Volunteer Association to carry out a charity performance of caring for children with autism, "Surrounding Love". Continued to speak for this group and call on the public to understand and understand autistic children.